I Vaccine Definitions, Technology Classification, and Full Industry Chain Overview
The Nature and Classification Framework of Vaccines
Vaccines are biological products that simulate pathogen infections and activate the human immune system to produce specific protection. Their core logic is to exchange controlled risk for long-term immunity against high-risk infections: by exposing the body to pathogen-related antigens, B cells are trained to generate neutralizing antibodies and T cells to establish cellular immune memory, so that when a real pathogen invades, the immune system can quickly recognize and eliminate the threat, compressing rates of severe illness, hospitalization, and death to extremely low levels.
The vaccine classification system has multiple dimensions. By technical pathway, vaccines can be divided into seven major platforms; by use, into prophylactic and therapeutic vaccines; by administrative classification, into Class I (government-purchased and free) and Class II (self-pay) vaccines under China's national immunization program.
Seven Major Technology Platforms
Platform 1: Inactivated Vaccines
Inactivated vaccines kill pathogens through physical (heat inactivation, UV irradiation) or chemical methods (formaldehyde, β-propiolactone), retaining surface antigen structures so they are no longer infectious but can still elicit immune responses. Their advantages are mature process, high stability, and long safety records; disadvantages include relatively weaker immunogenicity (lacking the complete immune stimulation of live pathogens), typically requiring multiple doses, and often needing adjuvants to enhance immune responses. Representative products include CNBG's COVID-19 inactivated vaccine (BBIBP-CorV), Chengda Bio's human rabies vaccine (Vero cell substrate, 4- or 5-dose schedule), Hualan's quadrivalent influenza split vaccine (IIV4), and various hepatitis B and A inactivated vaccines. The inactivated platform demonstrated large-scale production capability during the COVID-19 pandemic — Sinovac's CoronaVac accumulated production exceeding 3 billion doses.
Platform 2: Live Attenuated Vaccines
Live attenuated vaccines use live pathogens that have been long-term passaged in the laboratory to greatly reduce virulence while retaining replication capacity and immunogenicity. Since live vaccines can replicate limitedly in vivo, their immunogenicity closely resembles natural infection, typically requiring only 1–2 doses to produce lasting protection and eliciting both humoral and cellular immunity. Major risks involve immunocompromised individuals who should not be vaccinated, and relatively strict cold chain requirements. Domestic representative products include: Bavarian Nordic's intranasal influenza live attenuated vaccine (LAIV, one of the few commercially available LAIV products globally in 2025, included in the WHO Global Influenza Action Plan) and varicella live attenuated vaccines (with suppliers including Bavarian Nordic, North China Biology, etc.).
Platform 3: Recombinant Protein Vaccines
Recombinant protein vaccines use genetic engineering to introduce target antigen genes into expression systems (E. coli, yeast, insect cells, mammalian cells) for large-scale production of purified recombinant protein antigens as immunogens. Representative products include: Wantai's bivalent HPV vaccine (Cecolin®, based on L1 protein VLP self-assembly technology, WHO PQ certified in 2024), Zhifei Longcom's recombinant COVID-19 protein vaccine (ZF2001, based on RBD trimer antigen, first recombinant protein COVID vaccine in China), and various recombinant hepatitis B vaccines (HBsAg expressed in CHO or yeast systems). This platform is safe with no need to handle live pathogens, and easily scalable; the main weakness is that pure protein antigens have relatively weak immunogenicity, so all commercial products require adjuvant systems (aluminum hydroxide, AS04, etc.).
Platform 4: Viral Vector Vaccines
Viral vector vaccines use modified viruses (commonly adenoviruses Ad5, Ad26, chimpanzee adenovirus ChAdOx1) as delivery vectors, integrating target antigen genes into the vector genome, and briefly expressing target proteins within host cells after injection to induce strong humoral and cellular immune responses. The main challenge is pre-existing immunity to the adenovirus used, which can reduce vaccine effectiveness. CanSino Biologics is the flagship domestic enterprise for adenovirus vector vaccines: Ad5-nCoV (Convidecia) was approved for conditional marketing and commercialized in 2021; in 2022, the world's first inhaled adenovirus vector COVID-19 vaccine (Convidecia Air) began administration; and an inhaled tuberculosis booster vaccine (Ad5-TB, approved in Indonesia in 2025) further expanded adenovirus vector applications. Oxford-AstraZeneca AZD1222 produced over 2.5 billion doses globally before voluntarily withdrawing from major markets in 2024.
Platform 5: mRNA Vaccines
mRNA vaccines deliver messenger RNA sequences encoding target antigen proteins to the cytoplasm, where host cell ribosomes translate and express the target antigen to activate the immune system. No actual pathogen is required, eliminating biosafety risks; in theory, vaccine sequence design can be completed in weeks after antigen sequence determination. Core challenges include rapid in vivo mRNA degradation (requiring chemical modification such as N1-methylpseudouridine substitution), delivery efficiency (requiring LNP nanocarriers for protection and endosomal escape), and manufacturing process consistency control at scale. Pfizer-BioNTech's Comirnaty (BNT162b2) and Moderna's Spikevax (mRNA-1273) are landmark products. Fosun Pharma holds exclusive commercialization rights for BNT162b2 in Greater China.
Platform 6: Polysaccharide Conjugate Vaccines
Polysaccharide conjugate vaccines link bacterial capsular polysaccharides (T-cell independent antigens) to carrier proteins (diphtheria toxoid CRM197, tetanus toxoid, etc.) through chemical conjugation, converting T-cell independent into T-cell dependent immune responses, thereby producing effective memory immunity in infants under 2. This platform is the mainstream technical approach for childhood pneumococcal, meningococcal, and Hib vaccines. Representative products: Watson's 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13, Walvax®), Pfizer's Prevnar 13 and Prevnar 20, CanSino's MCV4 quadrivalent meningococcal conjugate vaccine (Mencovax®). Saccharide chain length control, saccharide/protein ratio, and residual free polysaccharide levels in the conjugation process are core quality control indicators and competitive barriers.
Platform 7: Combination/Multivalent Vaccines
Combination vaccines integrate antigens against different pathogens into a single formulation (e.g., pentavalent DTP-IPV-Hib); multivalent vaccines integrate antigens against different serotypes of the same pathogen (e.g., quadrivalent influenza, 9-valent HPV). Combination/multivalent vaccines can significantly reduce injection visits and improve compliance, but immune interference between antigens, formulation stability, and lyophilization excipient selection are core technical challenges.
Immune Interference Mechanism: When multiple antigens coexist in the same dose, interference patterns may include: ① carrier protein competition — multiple polysaccharides conjugated to the same carrier protein may divert carrier-specific T cells; ② antigen competition — the immune response to some antigens may be suppressed by others with stronger immunogenicity; ③ antigen-adjuvant interaction — some antigens may compete with aluminum adjuvant particles for adsorption sites. Technical solutions include precise ratio control, optimized dosing intervals, and adjuvant optimization.
Global Frontier: Sanofi's Capvaxive (PCV21, approved in 2025) represents a complex 21-valent system conjugated to CRM197; Moderna's mRNA-1283 and mRNA-1083 represent mRNA-based combination strategies, achieving "one shot, multiple protections" within a single LNP. Domestic multivalent gaps include the five/six-in-one vaccine (DTP-IPV-Hib series), still dominated by Sanofi's Pentaxim — CNBM Bio is the only domestic candidate with potential to fill this gap within the next 3–5 years.
Prophylactic vs. Therapeutic Vaccines
Prophylactic vaccines (the mainstream) build protective immune barriers in uninfected individuals. Therapeutic vaccines target already-infected or ill individuals — examples include hepatitis B therapeutic vaccines, HIV therapeutic vaccines, and personalized neoantigen mRNA tumor vaccines (Moderna mRNA-4157 combined with pembrolizumab for melanoma). Therapeutic vaccines are regulated differently from prophylactic vaccines (closer to biologics) and most are still in clinical stages.
Critical Quality Attributes (CQA) and Critical Process Parameters (CPP)
Modern vaccine manufacturing follows the ICH Q8/Q9/Q10 quality system framework (QbD, Quality by Design), requiring clear definition of CQAs and CPPs during development, and quantifying relationships between them to ensure batch-to-batch quality consistency.
Key vaccine CQAs include: potency/immunogenicity (expressed as IU/dose, μg/dose, or animal immunization results), purity (residual host cell proteins, residual DNA, formaldehyde, etc. below specified limits), particle size and uniformity (for VLP/LNP, PDI must be < 0.1–0.2), sterility, appearance, potency (in vitro or in vivo), and pH/osmolality.
Key CPP examples: cell culture temperature (±0.5°C), pH (±0.05), dissolved oxygen (35–50%), agitation speed; chromatography column load (mg/mL), elution buffer concentration, flow rate (cm/h); LNP preparation FRR, TFR, lipid concentration, N/P ratio; filling speed, vial temperature, needle diameter and fill volume.
The ICH Q8 framework allows companies to make process adjustments within validated design space without NMPA re-review, but post-approval process changes must be managed according to NMPA's Technical Guidelines for Pharmaceutical Changes of Marketed Biologics.
Full Industry Chain: Four-Layer Structure
The vaccine industry chain encompasses: upstream raw materials and core technologies (antigen bulk, adjuvant systems, cell culture media, single-use bioreactors, filtration membranes, chromatography resins, LNP lipid components, IVT enzymes); midstream core manufacturing (from master cell/seed bank management through purification, viral inactivation, formulation, filling, lyophilization, to lot release); downstream circulation and vaccination (cold chain distribution, CDC systems, vaccination clinics); and auxiliary materials (vials, syringes, rubber stoppers, aluminum caps, cold chain equipment).
Vaccine stability research is essential to ensure product efficacy throughout distribution. Key challenges include freeze-thaw cycles for aluminum-adjuvanted vaccines (strict prohibition on freezing), and freeze-thaw and multiple-thaw restrictions for mRNA/LNP vaccines (LNP aggregation and mRNA degradation).
Strategic Position and National Security of the Vaccine Industry
Vaccines are not merely public health products but national strategic-level biosafety infrastructure. Three core dimensions: technology autonomy (independent R&D without dependence on foreign patents/technology); production capacity (rapid scale-up within 3–6 months to meet national immunization needs); and supply chain autonomy (full domestic sourcing of key materials, equipment, and process technology).
China demonstrated strong production mobilization and commercial execution during COVID-19 with inactivated vaccines (CNBG, Sinovac), producing over 4 billion doses and supplying 60+ countries. However, gaps in technological diversity (especially mRNA platforms) and supply chain autonomy (LNP lipids, IVT enzymes, high-end filtration membranes) remain relative to Western leaders, driving continued policy support for China's vaccine industry.
II Global Vaccine Landscape: FY2025 Data and Strategy of Six Major Players
Global Market Overview
The global vaccine market in 2025 is estimated at approximately US$105 billion, significantly down from the COVID-19 peak (2021–2022: ~US$150 billion) due to continued decline in COVID vaccine demand. However, the foundational vaccine market excluding COVID-19 maintains healthy growth. Six major multinational pharmaceutical companies (Pfizer, Merck, GSK, Sanofi, Moderna, AstraZeneca) account for approximately 80% of global market share — a highly oligopolistic structure.
Three forces driving non-COVID growth: penetration rates of high-price innovative vaccines (Shingrix, Prevnar) continuing to rise in high-income countries; expanding global HPV vaccination coverage; and improving vaccine accessibility in low-income countries through COVAX/GAVI.
Global Vaccine R&D Pipeline Competition
In core non-COVID tracks, major pharmaceutical companies compete across five directions: adult/pediatric RSV, mRNA influenza, improved zoster, HIV vaccines (mRNA/broadly neutralizing antibody combinations), and CMV vaccines. The RSV space saw three products launched in 2023–2025 (Arexvy, Abrysvo, mRESVIA). mRNA influenza is the most intensely competitive pipeline race for 2025–2028. Moderna's mRNA-1647 (CMV) has already submitted BLA to FDA, is on track to become Moderna's third approved mRNA product.
Global Vaccine Market by Category (2025 estimates):
| Category | Global Market (USD billion) | Key Competition |
|---|---|---|
| COVID-19 vaccines (annual boosters) | 18–22 | Pfizer/Moderna duopoly |
| Pneumococcal conjugate | 7–8 | Pfizer Prevnar dominant |
| Influenza | 6–7 | Sanofi/GSK/Pfizer/CSL |
| HPV | 6–7 | Merck dominant, domestic challengers |
| Zoster | 5–5.5 | GSK Shingrix monopoly |
| RSV vaccines/prevention | 1.5–2.5 | GSK/Pfizer/Moderna |
| Meningococcal | 2–2.5 | GSK/Pfizer/Merck |
| Rotavirus | 1.2–1.5 | GSK/Merck |
| Varicella/zoster (live attenuated) | 0.8–1.2 | Merck Varivax dominant |
| Other (EPI products) | 20+ | Highly fragmented |
Pfizer: Pneumococcal Conjugate Leader
Pfizer is the world's largest single vaccine company. Its three-stage strategic evolution: the 2009 Wyeth acquisition brought Prevnar 13 (then the world's highest-selling single vaccine at peak ~US$6+ billion/year); 2020–2021 BioNTech mRNA collaboration produced Comirnaty, making Pfizer's annual revenue exceed US$100 billion in 2021–2022; 2023–2025 saw Prevnar 20 and Abrysvo (RSV protein subunit for adults 60+, approved 2023; for pregnant women, 2024).
FY2025 vaccine revenues: Prevnar family ~US$6.2–6.5 billion; Comirnaty H1 2025 ~US$945 million (+72% YoY). In China, Prevnar 20's regulatory submission is progressing; Comirnaty faces complex regulatory challenges for mainland commercialization.
Merck (MSD): Gardasil 9 Faces China Market Disruption
Merck's core vaccine asset is Gardasil 9. FY2024 global revenue US$8.6 billion, down ~3% YoY, primarily due to China market collapse — China once contributed 40–50% of Gardasil global sales but saw dramatic decline in 2024. After Wantai's 9-valent HPV vaccine launched in June 2025 at 499 CNY/dose (38% of Gardasil 9's price), Merck paused China shipments and fully reevaluated China strategy. In global markets, Merck is offsetting China losses through: ① expanding GAVI-funded HPV programs in Africa and Southeast Asia; ② promoting HPV vaccination in adult men (ages 27–45) in the US and Europe; ③ seeking incremental markets in the Middle East and Latin America.
GSK: Shingrix Drives High-Quality Growth
GSK is one of the world's largest vaccine companies by sales (excluding Pfizer). FY2025 total vaccine revenue GBP 92 billion (US$120 billion), up ~2% YoY, driven by Shingrix.
Shingrix: Contains gE recombinant protein antigen + AS01B adjuvant (MPL and saponin QS-21), 90–97% protection efficacy with two-dose schedule, maintained in those 70+. FY2025 annual revenue GBP 3.6 billion (US$4.7 billion). In China, Shingrix is distributed through Zhifei Biologics' channel network.
Arexvy (RSV vaccine): Approved 2023 for adults 60+ for RSV prevention. After ACIP changed recommendation from universal to shared clinical decision-making in 2024, uptake declined. FY2025 revenue ~GBP 600 million, growth constrained.
Sanofi: Traditional Influenza and Combination Vaccines
Sanofi Pasteur's core: influenza vaccines and combination vaccines.
Influenza vaccines: Fluzone HD-IIV4 (quadrivalent high-dose, 4× antigen content) for adults 65+, significantly superior protection versus standard dose in elderly — preferred US option for senior influenza vaccination. Sanofi holds ~25–30% global influenza vaccine market share.
Pentaxim five-in-one: DTaP-IPV-Hib five-valent vaccine, priced at ~900–1,200 CNY/dose in China's private vaccination channels, with stable market share due to reduced injection visits.
Sanofi's pipeline includes RSV-MPV combination mRNA candidates, seasonal influenza mRNA vaccines, and MenABCWY (meningococcal five-in-one). Its mRNA platform is approximately 2–3 years behind Pfizer-BioNTech and Moderna.
Moderna: Deep Commercialization of mRNA Platform
Moderna is a leader in mRNA platform technology. FY2025 revenue guidance: US$1.5–2.5 billion (mainly from Spikevax annual formulation updates), down >85% from FY2022 peak.
mRESVIA (mRNA-1345, RSV mRNA vaccine): Approved by FDA 2024 for adults 60+, approved in 40 countries in 2025. Commercialization is below expectations due to ACIP strategy adjustments and GSK Arexvy's first-mover advantage.
mRNA-1010 (influenza mRNA): Phase III trial against standard IIV4. Mid-2024 interim analysis showed H3N2 seroconversion rate did not meet non-inferiority, but H1N1 and B subtypes met targets. Moderna launched an optimized version (mRNA-1010 v2) for additional Phase III evaluation in the 2025–2026 influenza season.
mRNA-1647 (CMV): Phase III MELD study demonstrated efficacy in women of childbearing age. Moderna submitted BLA to FDA in 2025 — Moderna's third mRNA product to reach application stage after Spikevax and mRESVIA.
Novavax: Defender of Recombinant Protein Route
Novavax uses recombinant protein nanoparticle vaccines (with Matrix-M saponin adjuvant). NVX-CoV2373 (Nuvaxovid) is the only recombinant protein COVID-19 vaccine. In 2025, Novavax reached a ~US$1.7 billion licensing and commercialization deal with Sanofi — Nuvaxovid's commercial rights in certain regions plus Novavax influenza protein vaccine licensing.
Matrix-M adjuvant strategic value: Despite Novavax's commercial difficulties, Matrix-M (semi-solid liposome complex containing saponin QS-21 and QS-7 fractions) represents one of the most advanced commercially available strong adjuvants globally, alongside GSK's AS01B. It induces Th1/Th17 cellular immunity and strong neutralizing antibodies.
AstraZeneca: COVID Exit, Bet on RSV Monoclonal Antibody
AstraZeneca proactively withdrew AZD1222 from major markets in 2024 due to rare adverse event controversies (thrombosis with thrombocytopenia syndrome, TTS). However, Beyfortus nirsevimab (RSV long-acting neutralizing monoclonal antibody, for infants, co-developed with Sanofi) has become a major commercial success story in 2023–2025, with ~75–80% protection efficacy against infant RSV lower respiratory tract infections.
III PEST Analysis: Policy Environment, Regulatory Framework, Economic Foundation, and Sociotechnological Drivers
Political & Regulatory
Regulatory architecture: China's vaccine regulatory system underwent systematic reconstruction after the 2018 Changchun Changsheng incident. NMPA is the highest regulatory authority; CDE handles marketing authorization applications; NIFDC (National Institutes for Food and Drug Control) performs lot release testing. Vaccines are classified as "special medicines" and subject to the strictest lifecycle management.
Lot release system: China requires mandatory Batch Release for each vaccine lot before marketing — each batch must be tested and certified by NIFDC or provincial agencies. NMPA has further strengthened the lot release review mechanism in 2024–2025.
National EPI expansion: China's EPI currently covers 14 vaccines preventing 15 diseases. Major development: From November 10, 2025, HPV vaccines are officially incorporated into the national EPI, providing free two-dose bivalent HPV vaccination to eligible girls born after November 10, 2011, expected to benefit 20–30 million eligible girls annually. Industry widely anticipates that quadrivalent influenza, zoster (50+), and adult pneumococcal conjugate vaccines may also enter the EPI candidate list within 3–5 years.
Price regulation history: After the 2016 Shandong vaccine incident, China implemented "two-ticket system" reforms, greatly reducing distribution layers and gray intermediaries. Provincial listing/tendering platforms make vaccine prices highly transparent. In 2024–2025, the minimum listed price for bivalent HPV vaccines dropped to ~27.5–63 CNY/dose in various provincial charity programs, down 70–85% from 2020 prices of ~173–200 CNY/dose.
Future volume-based procurement (VBP) scope: The likelihood of national VBP for 9-valent HPV or zoster vaccines is one of the biggest policy uncertainties for 2026–2030. Trigger conditions typically include: ≥3 domestic competitors (9-valent HPV currently has 2; reaching 3 with Watson's entry), large market size (~10+ billion CNY scale), and sufficient price headroom. Earliest possible 9-valent HPV VBP timing: 2027–2028.
WHO PQ and international regulations: WHO Prequalification (PQ) is the necessary threshold for domestic vaccines to enter COVAX/UNICEF/PAHO global procurement systems. China's vaccine PQ-certified product count is 10, far behind India's SII (30+), making accelerated PQ certification a key path to improving international competitiveness.
Economic
Macroeconomic foundation: China's per capita GDP in 2025 is US$13,000, with a nominal GDP of ~US$18 trillion, entering the upper-middle income country range. The expanding middle class (400–500 million people) provides a continuously growing payment capacity base for Class II self-pay vaccines (zoster, 9-valent HPV, quadrivalent influenza).
Vaccine market economic characteristics: Policy-strongly-driven (EPI expansion can instantly bring tens of millions of additional doses); significant information asymmetry (price sensitivity lower than OTC drugs); significant brand premium (5–10× price gap between imported and domestic); and high inventory risk (18–36 month expiry, as exemplified by Zhifei's ~20 billion CNY inventory crisis).
Health economic evaluation: ICER (Incremental Cost-Effectiveness Ratio) is the core policy tool. HPV vaccine EPI inclusion modeling shows ICER ~3,000–10,000 CNY/QALY, significantly below China's GDP threshold of ~100,000 CNY/year per capita — the core quantitative basis for the policy decision.
Medical insurance: Class II self-pay vaccines are currently not covered by basic medical insurance. Some commercial insurance products have begun covering HPV and zoster vaccines, but penetration remains low.
Social
Aging population: China's 65+ population is 16% of the total (220 million) in 2025, projected to exceed 22% by 2035. Aging is the fundamental driver of the adult vaccine market for zoster (high-risk 50+), pneumococcal (elderly/chronic disease patients), and high-dose influenza vaccines.
Rising public health awareness: COVID-19 significantly increased public recognition of vaccine efficacy and importance; HPV vaccine's cervical cancer prevention concept (with ~100,000 new cases annually) is deeply embedded; social media spread of zoster's "elderly shingles" has greatly increased awareness of adult vaccines.
Vaccine hesitancy: Social media anti-vaccine/rumor content spreading on Weibo, WeChat, and Douyin brings challenges to HPV vaccine ("side effects" rumors) and zoster vaccine ("only imported vaccines are effective" bias) promotion.
Diversified vaccination channels: In addition to traditional community health centers and maternal and child health hospitals, private vaccination clinics (chain clinics like Tongkang, Xifoo, Meinuojian) have rapidly expanded, providing convenient access points for mid-to-high-end Class II vaccines.
Disease burden data: Cervical cancer: ~100,000–120,000 new cases/year in China; zoster: ~2–3 million new cases/year, 50+ incidence ~1,000–1,500/100,000; pneumococcal invasive infection: ~600,000–800,000 cases/year; influenza: ~80,000–100,000 excess deaths/year; rabies: ~1,600–2,000 human rabies vaccine injection episodes/year; RSV: ~6–8 million under-5 lower respiratory tract infections/year.
Technological
mRNA/LNP technology revolution: COVID-19 vaccine success has proven the industrial viability of mRNA+LNP platforms, rapidly extending to influenza, RSV, HIV, CMV, and oncology. Key IP issues (Arbutus/Genevant holding core ionizable lipid patents) remain a core IP risk for domestic mRNA vaccine companies.
Artificial intelligence and big data: AlphaFold2 revolutionized protein structure prediction; machine learning applied to influenza virus evolution prediction, vaccine safety signal monitoring (AEFI big data analysis).
Novel delivery routes: Mucosal delivery (intranasal, aerosol inhalation) can establish local secretory IgA protection in the respiratory tract; transdermal microneedle patches (soluble microneedle arrays) deliver vaccines at room temperature without needles — promising for large-scale vaccination in developing countries.
IV China Vaccine Market Scale: Category Breakdown and Market Concentration
Total Market Scale and Growth Drivers
Total estimate: Excluding COVID-19 vaccine-specific contributions (2020–2023), China's vaccine market (Class I + II) exceeded 100 billion CNY in 2023, entering the 100-billion-yuan market era. In 2025, factoring in HPV price wars (downward pressure on total scale), pneumococcal vaccine volume growth, zoster vaccine rapid penetration, and steady improvement in influenza vaccination rates, estimated market size is ~120–150 billion CNY. Class II (self-pay) vaccines contribute ~70–75% of revenue; Class I (EPI, lower government procurement prices) ~25–30%.
Main growth themes: ① Rise of adult self-pay vaccines — zoster, HPV (9-valent age expansion), quadrivalent influenza are core adult vaccine categories; ② domestic premium substitution — domestic PCV13 gradually taking Prevnar 13 share, domestic 9-valent HPV opening price space; ③ EPI expansion policy dividends; ④ export increments — 2025 vaccine export ~US$324 million (up 52.6% YoY).
HPV Vaccine Market Deep Dive
Category structure: Five approved HPV vaccines: ① Wantai bivalent (Cecolin®, ages 9–45); ② GSK bivalent Cervarix (ages 9–45); ③ Merck quadrivalent Gardasil (ages 20–45); ④ Merck 9-valent Gardasil 9 (ages 9–45); ⑤ Wantai 9-valent (Cecolin 9®, ages 9–45, approved June 2025). Watson Bio's 9-valent HPV vaccine is in Phase III clinical sprint.
Scale estimate: 2024 9-valent HPV lot release ~31.14 million doses; at Gardasil 9's ~1,298 CNY/dose, imported 9-valent revenue ~40 billion CNY; total HPV vaccine market ~100–120 billion CNY. In 2025 with domestic 9-valent at 499 CNY/dose, total injection volumes may increase but average prices shift significantly downward.
Competitive evolution: 2025 breaks Gardasil 9's monopoly — market moves from "monopoly" to "Sino-foreign competition"; when Watson enters (2027), moves to "multi-brand competition."
Pneumococcal Conjugate Vaccines (PCV)
Market structure: Pfizer Prevnar 13 has long led the 0–2 age infant/toddler segment. Watson's PCV13 (Walvax®, launched 2020) is the only domestic PCV13 with ~30–40% market share in 2025; estimated total PCV market ~80–100 billion CNY. Prevnar 20 (20-valent, application in progress in China); Watson PCV15 in clinical stage.
Zoster Vaccine
Market scale and growth: 2021 market was nearly zero (GSK Shingrix entered May 2020); 2025 estimated ~80–120 billion CNY, CAGR exceeding 100%, the fastest-growing vaccine subsegment in China.
Competitive landscape: Duopoly — GSK Shingrix (~90%+ protection efficacy, 2-dose schedule; distributed via Zhifei in China) and Bavarian Nordic Ganwei (live attenuated VZV, single dose, ~50%+ efficacy). "Buy one get one free" promotions in 2025 significantly lowered barriers but compressed corporate profits.
RSV Vaccine and RSV Prevention
RSV is the leading pathogen of lower respiratory tract infections in infants globally and a major cause of hospitalization in adults 65+. Global RSV prevention had breakthrough advances in 2023–2025 with Arexvy, Abrysvo, mRESVIA, and Beyfortus.
Domestic RSV gap: China lags ~4–5 years behind the US in RSV prevention products. Beyfortus approved in Hong Kong in 2024, application pending on mainland (expected 2026–2027). Adult RSV vaccines have not yet started domestic application. Domestic RSV vaccines are in preclinical or Phase I stages, 3–5 years from commercialization.
RSV market commercial potential: If Beyfortus approved in 2026–2027 for infants 0–1, at 500–1,500 CNY/dose, potential market ~10–60 billion CNY/year. Adult RSV vaccines (65+): if 5% penetration at ~2,000–3,000 CNY/full course, ~220–330 billion CNY market. RSV is the largest new incremental market in adult vaccines for the next 5–10 years.
Adult Pneumococcal Vaccines: The Next Scale Market
China's 65+ elderly (~220 million in 2025) have only ~2–5% pneumococcal vaccine coverage, versus 60–70% in the US (Medicare-covered). Barriers include insufficient awareness, non-reimbursed cost (self-pay ~350–700 CNY/dose), lack of national adult vaccine recommendation system, and inadequate physician recommendation rates.
If Prevnar 20 is approved in China (2026–2027) and coverage reaches 10% (22 million people) at ~1,000 CNY/person, incremental market size ~22 billion CNY — more than twice the existing pediatric PCV market.
Influenza Vaccine
China's influenza vaccination rate is ~3–4% (2024), far below the 40–70% in Europe/US. Quadrivalent influenza vaccines (IIV4) are now standard. Major suppliers include Hualan Vaccine (annual capacity ~70 million doses, China's largest), Kinding Bio, Beijing Weigo, and Sanofi. Bavarian Nordic's intranasal influenza LAIV (children 3–17, new liquid formulation certificate in August 2025) has differentiated competitive advantages in the pediatric segment.
CR10 Market Concentration
China's vaccine industry CR10 is ~65–70%, with regional small and medium vaccine companies (40–50 holding production licenses) still occupying some market space. Under dual pressure from price wars and rising compliance costs, small and medium enterprises face increasing survival pressure, with clear industry consolidation trends.
V Industry Chain Breakdown: Upstream Key Materials and Manufacturing Equipment
Antigen Bulk Production Technology
Inactivated vaccine bulk production: Viruses cultured in cells (Vero, MDCK) or chicken embryos at high viral titers, then harvested and chemically inactivated, purified by ultracentrifugation or column chromatography. Performed in BSL-2/3 biosafety laboratories with high safety requirements. Main culture equipment: roller bottles/cell factories (low-cost, traditional) and single-use bioreactors (wave-type or stirred-tank, domestic substitution rate >50%).
Recombinant protein/VLP bulk production: Target antigen genes introduced into expression systems (CHO cells, yeast, E. coli) for fermentation or cell culture; harvested, clarified, ultrafiltered, purified by chromatography (protein A affinity, ion exchange, size exclusion), achieving purity ≥98%. Culture media (pharma-grade, serum-free) is a key consumable; domestic companies AuPharma, BioStar have made significant progress in serum-free CHO media, but high-end concentrated feed media still have import dependence.
mRNA bulk production: Using plasmid DNA as template, in vitro transcription by T7 RNA polymerase, followed by 5' capping, poly(A) tailing, modified nucleoside substitution (N1-methylpseudouridine), ultracentrifugation, and ion exchange chromatography to remove residual double-stranded RNA. T7 RNA polymerase and capping enzymes are mainly imported from Thermo Fisher and NEB; domestic substitution is ~30–40%, a key bottleneck. LNP encapsulation via microfluidic mixing of mRNA with ionizable lipid and three other lipid components is the core formulation step.
Adjuvant System Domestication Status
Alum (aluminum hydroxide): Most widely used, lowest cost, complete domestic supply chain.
AS01B: GSK proprietary, contains MPL and saponin QS-21 — core of Shingrix's high protection efficacy. Domestic research on AS01B-level strong adjuvants (Xiamen University, Academy of Military Sciences) is being pursued but commercial application is still years away.
CpG 1018: Dynavax technology, used in Heplisav-B and Novavax NVX-CoV2373. Domestic replica CpG adjuvants have academic research basis but no commercial breakthrough.
MF59 and AS03 emulsion adjuvants: Oil-in-water emulsions; no domestic commercial products.
Single-Use Bioreactors (SUB) and Continuous Manufacturing
Domestic single-use bioreactors (Ausibo Bio, BoZhida, etc.) had over 50% market share by end of 2024, but key sensors (pH electrodes, pO2 electrodes) still primarily rely on imported brands (Sartorius, Broadley-James).
Perfusion culture: Continuous feed and harvest maintains cell density >5×10⁷ cells/mL versus ~5–10×10⁶ for batch culture — significantly higher volumetric yield. Major domestic vaccine companies are gradually adopting perfusion culture, but process validation is time-consuming.
Virus Inactivation and Removal Validation
Virus inactivation: Chemical inactivation with formaldehyde or β-propiolactone, requiring viral inactivation kinetics studies demonstrating ≥6-log reduction. Residual formaldehyde must be controlled below safety thresholds (generally ≤0.02%).
Virus removal validation: For recombinant protein vaccines using animal-derived materials (cell substrates, serum, trypsin), virus safety risk assessment and virus removal validation (virus spiking studies) are required per ICH Q5A guidelines.
Cold Chain Full-Chain Coverage
Class I vaccine cold chain: Province CDC → City CDC → County CDC → Town health center/community health center → vaccination point, 2–8°C throughout.
Class II commercial cold chain: Vaccine companies → licensed distribution companies → sub-distributors → vaccination units, 2–8°C.
Ultra-low temperature cold chain: mRNA vaccines (-60 to -80°C) require specialized ultra-low temperature storage and transport. Domestic Haier Biomedical and Zhongke Meiling have full product lines from 2–8°C vaccine refrigerators to -86°C ultra-low temperature freezers.
Packaging Materials Domestication
Vials: 2 mL, 5 mL, 10 mL borosilicate glass (Type I) vials; Shandong Zhengchang and Pharmaceutical Glass (600456) are major domestic manufacturers for standard products. High-end ISO 15378-certified vials still partially imported from SCHOTT and Gerresheimer.
Rubber stoppers and aluminum caps: Domestic supply chain established (Xinhua Medical, Anhui Shunkang).
Prefilled syringes (PFS): Domestic PFS manufacturers include CanDeLai and Shandong Zhengchang (joint venture with Gerresheimer technology); high-end siliconized glass PFS still import-dependent.
VI Key Company Deep Analysis: FY2025 Performance and Strategic Directions
Zhifei Biologics (300122): Inventory Crisis and Transformation Challenges
Company profile: China's largest integrated vaccine agency and self-development company. Core competitive moat: exclusive agent for Merck HPV vaccines (quadrivalent, 9-valent Gardasil) in China. Self-developed products: recombinant tuberculosis vaccine (EC-TB), recombinant COVID-19 protein vaccine (ZF2001), and freeze-dried meningococcal ACYW135 polysaccharide vaccine.
FY2025 financial data: H1 2025: revenue 4.919 billion CNY (-73.06% YoY), net profit -597 million CNY (first H1 loss since 2010 IPO, worst H1 in history). First three quarters: revenue 7.627 billion CNY (-12.06% YoY), net profit -6.653 billion CNY (-156.1% YoY). FY2025 full-year loss forecast: 10.698–13.726 billion CNY.
Root cause: Large-scale inventory accumulation during HPV vaccine market peak (2021–2023), forming >20 billion CNY inventory. Market demand cooled from H2 2023; Wantai's 9-valent HPV launch at 499 CNY/dose in June 2025 created systematic price disruption; some inventory will expire in 2026.
Strategic response: Actively advancing recombinant TB vaccine (EC-TB) overseas registration and UN procurement; negotiating Merck agency agreement terms; entering GLP-1 weight-loss drug (Semaglutide) API and injection business as a second growth curve.
Watson Biologics (300142): PCV Core + 9-Valent HPV Sprint
Company profile: One of China's strongest self-development capability private vaccine companies, with "self-development + production + international expansion" as strategic core. Core products: PCV13 (Walvax®), bivalent HPV vaccine, and mRNA COVID-19 vaccine (with Abogen, Yunnan Watson-Abogen). Subsidiary Yuxi Watson specializes in PCV13 large-scale production with tens of millions of doses annual capacity.
FY2025 data: Q3 single quarter revenue ~557 million CNY; H1 revenue 1.154 billion CNY; PCV13 lot releases 1.8383 million doses (up 6.28% YoY). Core highlight: Watson PCV13 has established local production in Indonesia with Bio Farma — the first domestic self-developed product to achieve overseas local manufacturing, a landmark technology export case.
R&D pipeline: ① 9-valent HPV vaccine (Phase III sprint, expected to apply for approval 2026–2028); ② PCV15 (clinical stage); ③ mRNA COVID-19/RSV vaccine (with Abogen); ④ influenza vaccine pipeline.
Wantai Biologics (603392): Domestic 9-Valent HPV Rewrites Market Landscape
Company profile: Based on 18 years of technical accumulation by Xiamen University's Prof. Jun-zhang Xia team, Wantai is the pioneer in domestic HPV vaccine self-development and the only company to commercialize a bivalent HPV vaccine with WHO PQ in China.
FY2025 core events: June 2025: Cecolin 9® received NMPA approval — first domestic 9-valent HPV vaccine globally, second after Merck's Gardasil 9 (FDA approved 2014). Antibody GMC for HPV52 and HPV58 subtypes 1.25× and 1.91× higher than Gardasil 9 respectively — theoretically stronger protection for Chinese women (HPV52/58 more prevalent in Asian populations). July 2025: Announced pricing at 499 CNY/dose (~38% of Gardasil 9's ~1,298 CNY/dose). Q3 2025: Market access obtained in 16 provinces, vaccination started in 7 provinces.
FY2025 performance pressure: Bivalent HPV revenue declined ~4.2 billion CNY YoY due to price wars; Wantai's H1 2025 net profit significantly in the red.
International expansion: Cecolin (bivalent HPV, WHO PQ obtained in 2024) registered in Morocco, Kazakhstan, Thailand, Cambodia, Nepal, etc. Cecolin 9 WHO PQ application expected to launch (estimated 2–3 year completion). WHO PQ completion for 9-valent will be significantly more commercially valuable than bivalent, as most upper-middle-income developing countries prefer 9-valent for national HPV EPI programs.
CanSino Biologics (688185/6185.HK): Adenovirus Vector Pioneer, MCV4 Sustains Profitability
Company profile: CanSino is China's most representative company in recombinant adenovirus vector technology. Technical highlights: ① World's first inhaled adenovirus vector COVID-19 vaccine (Convidecia Air, approved 2022 for emergency use); ② Inhaled tuberculosis booster vaccine (Ad5-TB, approved in Indonesia May 2025); ③ MCV4 Mencovax® (quadrivalent meningococcal conjugate vaccine, groups A/C/Y/W135, the company's core profit driver).
FY2025 data: Q1 2025: revenue 1.074 billion CNY (+20.02% YoY); H1 2025: revenue 382 million CNY (+26% YoY). ~90% of H1 revenue concentrated in MCV4, creating pipeline concentration risk.
Changchun Hi-Tech (000661) and Bavarian Nordic (688276): Varicella/Zoster/Nasal Influenza Pressure
Changchun Hi-Tech: Total parent, with vaccine subsidiary Bavarian Nordic (688276) as the second growth pillar. FY2025 H1 revenue and profit both declined YoY, with Bavarian Nordic's losses as the main drag.
Bavarian Nordic (688276): Key products: varicella vaccine, zoster vaccine (Ganwei, live attenuated), and nasal spray influenza LAIV (Bitai).
Varicella: price war with multiple suppliers has compressed market prices from 200+ CNY to ~50–80 CNY.
Zoster (Ganwei): competing with GSK Shingrix; 2025 Shingrix "buy one get one free" campaign compressed Ganwei's relative price advantage, severely impacted volumes.
Nasal spray influenza: unique nasal spray formulation; new liquid nasal spray certificate obtained in August 2025 (previously freeze-dried nasal spray), simplifying manufacturing and storage. Phase I clinical approved for adjuvanted quadrivalent influenza vaccine (BK-01) in June 2025.
Hualan Biologics (002007) and Hualan Vaccine (301204): Influenza Vaccine Leaders
Hualan Vaccine (spun off on STAR Market 2022, 301204) is China's largest quadrivalent influenza vaccine supplier with annual capacity ~70 million doses and market share ~15–20%. Core competitive advantage: decades of chicken embryo-based traditional influenza vaccine production experience.
In 2025, Hualan Vaccine is developing intranasal LAIV for influenza, actively exploring Southeast Asia and Africa export opportunities. Hualan Biologics' blood products business (albumin, immunoglobulins, coagulation factors) maintained good growth in 2025 due to increased plasma collection stations, providing important support to the group's overall performance.
Chengda Bio (688739): Rabies Vaccine Leader, International Expansion
Chengda Bio has been the domestic market share leader in human rabies vaccines since 2008.
FY2025 data: H1 2025 revenue 706.77 million CNY (-19.75% YoY), net profit 122.29 million CNY (-44.47% YoY), due to intensified domestic competition and decreased Japanese encephalitis inactivated vaccine revenue. International business (20+ country registrations, cumulative sales to 18 million people) growth partially offset domestic decline.
Technical system: Vero cell substrate purified cell culture (PCEC) vaccine: culture of fixed rabies virus strain (aG or PV strain), purified by sucrose density gradient ultracentrifugation or chromatography purification after formaldehyde inactivation. Zagreb 4-dose schedule (days 0, 7, 21, equivalent efficacy to Essen 5-dose) actively promoted. 20+ country registrations including new Indonesia certificate obtained in Q1 2025.
CNBG (National Biotech Group): State Enterprise Backing, Multi-Product Coverage
CNBG (China National Biotech Group) integrates six major biotech research institutes in Beijing, Wuhan, Chengdu, Shanghai, Lanzhou, and Changchun — China's most comprehensive vaccine supplier in terms of variety and capacity. Core products span hepatitis B, hepatitis A, Japanese encephalitis (live and inactivated), MMR, meningococcal, DPT, polio, and COVID-19 inactivated vaccines. CNBG COVID-19 inactivated vaccine (BBIBP-CorV) was one of COVAX's most important supply sources, with global shipments exceeding 1 billion doses.
Minhai Biologics: Key Participant in the Combination Vaccine Track
Minhai Biologics is developing a hexavalent combination vaccine (DTaP-HepB-IPV-Hib, 6 antigens) that would directly challenge imported pentavalent (Sanofi Pentaxim, ~900–1,200 CNY/dose) and hexavalent (GSK Infanrix Hexa) vaccines if approved. Phase III clinical enrollment is nearly complete; projected approval 2027–2028, which would be a domestic first in combination vaccines.
Sinovac: Deepening Post-COVID Strategic Positioning
Sinovac is one of the Chinese vaccine companies with the largest strategic adjustment post-COVID. Core developments: ① Products restructuring — advancing MDCK cell-based influenza vaccine (overcoming chicken embryo supply seasonality); ② mRNA platform exploration with partners; ③ International deepening — 10-year agreement with Brazil's Ministry of Health (US$7+ billion total, signed November 2025); establishment of local production cooperation in UAE; registrations advancing in Serbia, Colombia.
VII Industrial Belt Map: Six Major Manufacturing Bases and International Expansion
Beijing Biopharmaceutical Cluster: State Enterprise + Innovation Dual Drive
Beijing hosts China's highest density of vaccine R&D institutions and manufacturing bases. Key players: CNBG Beijing Biologics Research Institute (Daxing District, founded 1919, China's oldest biotech research institute); Sinovac Biotech Beijing (Daxing District, global COVID-19 inactivated vaccine largest supplier); CanSino Biologics Beijing Research Center (R&D headquarters); Zhongguancun Life Science Park (Haidian/Changping District, incubating mRNA/adenovirus vector startups including Abogen and StemiRNA).
TXG (Tianxia Gongchang) platform covers a large number of biopharmaceutical manufacturers and vaccine upstream supporting factories in the Beijing region, available to vaccine companies for sourcing raw materials, equipment, and contract manufacturing partnerships.
Shanghai Zhangjiang: mRNA Innovation and International Hub
Key players: Abogen (Pudong, mRNA-LNP platform leader with Harvard-background co-founders and proprietary LNP IP); Fosun Pharma Health (Pudong, holds Pfizer-BioNTech BNT162b2 exclusive commercialization rights in Greater China — commercialized in HK/Macau/Taiwan but mainland approval pending); CNBG Shanghai Biologics Research Institute (Pudong, JE live attenuated vaccine SA 14-14-2 strain supplier for international aid programs). Medical device and pharmaceutical equipment manufacturers cluster in Zhangjiang High-Tech Park and surrounding areas (Minhang, Jiading).
Chongqing: Zhifei Biologics Headquarters and Health Industry Belt
Chongqing is Zhifei Biologics' headquarters and core production base. The municipal government has listed healthcare as a strategic pillar industry, with Liangjiang New Area providing policy and land support.
Yunnan Yuxi: Watson Biologics PCV13 National Production Base
Yunnan Yuxi is Watson Biologics' core vaccine production base — Yuxi Watson (subsidiary) produces PCV13 Walvax® at large scale (tens of millions of doses capacity) in Yuxi High-Tech Zone Biopharmaceutical Park, phases I and II completed.
Xiamen: Wantai Biologics HPV R&D and Manufacturing Stronghold
Xiamen is Wantai's headquarters, leveraging Xiamen University's biological research strengths (Prof. Jun-zhang Xia's 20+ years of virology and vaccine R&D accumulation). Xiamen Haicang Biopharmaceutical Harbor forms a relatively complete ecosystem from vaccine R&D to APIs to formulations to testing. Wantai's bivalent and 9-valent HPV vaccine core production facilities are all in Xiamen; Xiamen University National Infectious Disease Diagnostics Reagents and Vaccine Engineering Technology Research Center provides R&D support.
Changchun: China's Oldest Vaccine Manufacturing Base
Changchun has China's longest vaccine manufacturing tradition (Changchun Biologics Research Institute established 1948, first biological products manufacturer in New China). Despite the 2018 Changchun Changsheng quality crisis severely damaging the Changchun vaccine industry, Bavarian Nordic (688276 in Changchun Hi-Tech Zone) is rebuilding the industry's credibility with nasal spray influenza LAIV, varicella, and zoster vaccines.
International Industrial Layout: Indonesia, UAE, Morocco
Chinese vaccine overseas industrial layout has evolved from emergency export during the pandemic to systematic strategic positioning, forming three main threads:
Southeast Asia local manufacturing: Watson PCV13 local manufacturing in Indonesia with Bio Farma is the "China vaccine technology export 2.0" model; CanSino tuberculosis vaccine approved in Indonesia for future local manufacturing cooperation.
MENA market (Middle East/North Africa): Sinovac established local vaccine production partnership in UAE (leveraging Abu Dhabi Health Services Company facilities).
Africa and Central Asia: Wantai bivalent HPV registered in Morocco, Kazakhstan, DRC, Ethiopia, and more countries — targeting GAVI/COVAX procurement system entry.
The biggest 2025 overseas milestone: Sinovac and Brazil's Ministry of Health signed a 10-year cooperation agreement with contract value exceeding US$700 million, including regular supply of influenza, meningococcal, and other vaccines — the largest single international order in Chinese vaccine history.
Institutional drivers of China vaccine international expansion: Health Silk Road diplomatic framework embedding vaccines in bilateral FTAs; policy financial institution (MDB, EXIM Bank, China-Africa Fund) buyer credit financing for target country procurement; NMPA-WHO technical dialogue and bilateral GMP mutual recognition efforts with ASEAN national regulators.
VIII Subsector Deep Dives: Eight Hotspot Topics
HPV 9-Valent Domestic Breakthrough: Pricing Revolution and Market Structure Restructuring
Cecolin 9's June 2025 approval at 499 CNY/dose is unquestionably the biggest event in China's vaccine industry in 2025 — its significance comparable to Gardasil's global first approval in 2006.
Technical background: HPV VLP (virus-like particle) technology is used for all commercially available HPV vaccines globally. Differences between manufacturers: L1 protein expression system (yeast vs. baculovirus-insect cells), adjuvant selection (Gardasil series uses AAHS proprietary aluminum adjuvant; GSK Cervarix uses AS04 with MPL+aluminum), and serotype coverage strategy. Cecolin 9's antibody GMC for HPV52 and HPV58 subtypes significantly exceeds Gardasil 9 — these subtypes are relatively more prevalent in Asian populations.
Age expansion potential: Current 9-valent approved age 9–45; FDA has approved up to 45+ for some populations. Male HPV vaccination (preventing anal cancer, penile cancer, oropharyngeal cancer, condyloma) is mainstream in Western countries but not yet approved for males in China — if future policy opens this, 50% additional target population.
Market projection: 2025: Cecolin 9 in 16 provinces, ~3–5 million doses/year; 2026: national coverage, Cecolin 9 ~20–30 million doses, Gardasil 9 ~8–12 million; 2027–2028: with Watson 9-valent entry, three-brand competition, total annual 9-valent doses potentially 60–80 million; 2030: domestic 9-valent penetration target 70–80%.
PCV: From 13-Valent to 15/20-Valent Serotype Coverage Race
PCV market logic: "more serotypes = higher market value." PCV13 has established stable position in China's pediatric market (~80–100 billion CNY); Prevnar 20 (20-valent, already US market, expected China approval 2026–2027) will open adult pneumococcal market; Watson PCV15 in clinical trials; Sanofi's Capvaxive (PCV21, US-approved 2025 for adults) starting Asia-Pacific applications.
mRNA Vaccine Post-COVID Transition: Platform Value Maximization
mRNA challenges: inherent mRNA instability (addressed by chemical modification and LNP encapsulation), LNP scale-up (microfluidic mixing from mL to L–100L scale), cold chain challenges (-60 to -80°C).
Domestic progress: Abogen (~1.5 billion CNY Series C), StemiRNA, SinoVaccine Deep Belief are the most active mRNA innovators, with influenza mRNA, RSV mRNA, tumor mRNA vaccines in various clinical stages.
Regulatory pathway: CDE published guidelines for COVID-19 mRNA vaccine chemistry/manufacturing/controls in 2020; subsequent guidelines for influenza, RSV mRNA vaccine evaluations are being continuously refined. First batch of domestic non-COVID mRNA vaccines is expected to apply for marketing 2027–2028.
Zoster and RSV: New Markets for Adult Preventive Medicine
Zoster market depth: 220 million Chinese 65+ elderly; if reaching European/US Shingrix penetration (30–40%), potential annual vaccination ~100–150 million doses; at ~1,200 CNY/full course, market ceiling ~600–900 billion CNY — 6–9× current ~10 billion. Current barriers: low awareness (especially rural), still relatively high price, insufficient medical system recommendation.
RSV prevention multi-layer layout: Infants and elderly are highest-risk RSV groups — Beyfortus (infant prevention) expected approval 2026–2027; adult RSV vaccines (Arexvy, Abrysvo, or domestic) expected commercial launch 2027–2029.
Quadrivalent Influenza Mainstreaming and Next-Generation Products
Next-generation product roadmap: High-dose quadrivalent (HD-IIV4, 60 μg antigen vs standard 15 μg) showing ~24% superior relative protection in 65+ — US and EU approved, Sanofi HD version in China application; adjuvanted IIV4 (MF59 or aluminum adjuvant); MDCK cell-based cc-IIV4 (no chicken eggs needed); recombinant influenza RIV4 (output not limited by chicken embryo availability).
Core variable for China's influenza vaccine market growth: vaccination rate — from current ~3–4% to the 2030 policy target of 10–15%, yielding 2–3× market capacity growth without price increases.
Rabies Vaccine and Japanese Encephalitis Vaccine
Rabies: ~12–15 million PEP exposure episodes/year in China, ~16–20 million human rabies vaccine doses administered/year. Market steady. Chengda Bio, Yisheng Bio, North China Jinta are major suppliers with competition trending toward price wars.
Japanese encephalitis (JE) vaccines: live attenuated (SA 14-14-2 strain, single dose) and inactivated (two-dose schedule), both incorporated into EPI, market relatively stable. SA 14-14-2 live attenuated vaccine is the main supply brand for global JE vaccine aid projects (GAVI, UNICEF).
Combination Vaccines: Domestic Five/Six-Valent Pathway
Five-in-one vaccine (Pentaxim) long dominated by Sanofi in China. Key barriers: acellular pertussis (aP) component process stability, compatibility verification of five antigens in a single formulation. Minhai Bio's hexavalent (adding hepatitis B to Pentaxim's five components) is in late clinical stages; projected approval 2027–2028.
International Expansion and BRI: Technology-for-Market 2.0 Phase
China vaccine export global market map: ~100 countries/regions, export total ~US$324 million (excluding COVID-19 specific). Geographic distribution: Asia ~45%, Africa ~30%, Latin America ~15%, other ~10%.
Brazil order: Sinovac-Brazil Ministry of Health 10-year agreement (US$700 million+, signed November 2025), including technology transfer and local production capacity building.
Indonesia model: Watson PCV13 local production with Bio Farma, effectively bypassing WHO PQ pure import pathway.
Africa market: Wantai bivalent HPV registered in multiple African countries, targeting GAVI/Africa CDC government procurement.
IX Technology Evolution: Platform Iteration and Manufacturing Upgrade Roadmap
mRNA Platform Technology Depth and Challenges
Sequence optimization: Codon optimization, UTR (untranslated region) optimization, nucleoside modification (N1-methylpseudouridine, N1-methylpseudocytidine) — core chemical modifications in Moderna and Pfizer mRNA vaccines.
Self-amplifying mRNA (saRNA): Introduces RNA-dependent RNA polymerase (RdRp) replicase gene sequences for intracellular self-amplification, reducing mRNA dose by ~10–100×. Theoretically significantly reduces manufacturing costs and LNP toxicity, but increased process complexity. Arcturus Therapeutics and CureVac lead globally; Abogen has early-stage research.
Circular RNA (circRNA): 5–10× more stable than linear mRNA (no 5'/3' ends, RNase-resistant), enabling longer translation duration. Domestic SinoVaccine Deep Belief (Chengdu) specializes in circRNA platform with patented Group I intron-mediated self-catalytic cyclization, most active circRNA company in China. Main challenges: cyclization efficiency (60–80%), residual linear mRNA removal, and IRES activity regulation precision.
LNP technology innovation: Next-generation ionizable lipids to reduce toxicity and enhance endosomal escape; targeted delivery LNP (antibody/peptide modification) for organ-specific delivery, reducing off-target lipid accumulation.
Recombinant Protein and VLP Engineering Advances
Self-assembling protein nanoparticles (SAP): SpyCatcher-SpyTag system displays target antigens on nanoparticle surfaces, forming regular dense epitope arrays that significantly enhance B cell activation efficiency. Walter Reed Institute's ferritin nanoparticle (FluNP-HA) for influenza is a representative SAP application. Xiamen University and Peking University School of Pharmacy have SAP technology research.
AI-Assisted Antigen Design
Three core AI vaccine R&D applications: ① Structure prediction and epitope design (AlphaFold2 and RoseTTAFold accelerating antigen design); ② Epidemiological prediction and strain selection (AI-assisted viral sequence clustering and evolutionary tree construction supporting WHO annual influenza strain selection); ③ Vaccine schedule optimization (mathematical modeling and ML for precise assessment of different vaccination strategies).
mRNA Vaccine Large-Scale Production Economics
Construction cost and flexibility: One mRNA vaccine production line (microfluidic mixing, mRNA IVT, LNP encapsulation, ultra-low temperature filling) costs ~300–800 million CNY — significantly less than inactivated vaccine lines (BSL-2/3 facilities, 1–3 billion CNY). The mRNA platform's "universality" allows quick switching between different antigen mRNA vaccines on the same line.
Raw material cost structure: LNP lipid components ~30–40% of cost; mRNA IVT enzymes and NTP substrates ~20–25%; plasmid DNA template ~10–15%; ultra-low temperature filling ~10–15%; other excipients/packaging ~10–20%. Domestic substitution of LNP lipids and T7 polymerase could reduce unit cost by 30–50%.
Adenovirus Vector Multi-Indication Platformization
CanSino's adenovirus vector platform has demonstrated commercial viability in COVID-19 (Ad5-nCoV), inhaled COVID (Convidecia Air), tuberculosis booster (Ad5-TB, Indonesia approved). Next evolution: ① Using different serotype adenoviruses (Ad26, ChAd155) to address Ad5 pre-existing immunity; ② Improved inhaled formulation (more precise particle size control); ③ Multivalent adenovirus vector vaccines (simultaneously expressing multiple pathogen antigens).
Novel Delivery Route Commercialization Progress
Aerosol inhalation: CanSino has commercialized inhaled COVID-19 vaccine. Key technical challenges: ① particle size control (MMAD ~1–5 μm for alveolar deposition); ② nebulizer compatibility; ③ dosing accuracy (significant inter-individual variability in actual pulmonary deposition). Mucosal immunity advantage: nasal/oral respiratory tract-administered vaccines can induce local secretory IgA (sIgA) at the first line of viral defense.
Nasal spray: Bavarian Nordic's intranasal influenza LAIV (2025 liquid version certificate) is the only commercialized intranasal vaccine in China, with significant export potential.
Microneedle patch: Soluble microneedles (vaccine formulation shaped into needle protrusions, dissolving after skin application to release antigen in dermis). Core advantages: room temperature storage, painless, self-administration. Tsinghua University, Sun Yat-sen University affiliated hospitals have prototype validation; 3–5 years to commercialization.
X Risk Matrix: Multidimensional Risks Including Policy, Safety, Technology, and Market
National EPI Price Orientation and Potential VBP Impact
HPV vaccine inclusion in EPI means bivalent products will be procured at government pricing (~20–60 CNY/dose, far below market self-pay prices) in large volumes, with Wantai and Watson's bivalent HPV revenue migrating from high-margin self-pay to low-margin Class I markets. Larger policy risk: "whether 9-valent vaccine will be incorporated into EPI or national VBP within 3–5 years" — if so, significant downward price revision for Watson and Wantai's 9-valent products.
Safety Events and Lot Release Quality Control
The 2018 Changchun Changsheng "DTP + rabies vaccine record falsification" incident was China's worst quality crisis, triggering a public trust crisis in domestic vaccines broadly. The 2019 Vaccine Administration Law significantly strengthened production record integrity requirements, lot release prerequisites, and punishment severity. In 2025, monitoring intensity continues rising; compliance costs (GMP renovation, digital traceability system investment) increase accordingly.
Overseas Registration and WHO PQ Barriers
WHO PQ certification typically takes 3–5 years and costs millions to tens of millions of USD, with key bottlenecks in: ① production site inspection (WHO GMP, slightly different from domestic GMP standards); ② independent clinical data review; ③ labeling and product dossier compliance. For resource-limited smaller companies, PQ certification cost is a significant barrier.
Systematic Failure Risk in Innovative Vaccine R&D
mRNA vaccine Phase III results for non-COVID indications remain uncertain — Moderna mRNA-1010 influenza vaccine failed to meet primary efficacy endpoint in interim analysis. R&D cycle from Phase I to approval averages 10–15 years at 500 million to 2 billion CNY investment. International sanctions (key equipment, LNP lipids, IVT enzymes import restrictions) and IP litigation (especially LNP core patent litigation) are exogenous variables requiring risk management priority.
Cold Chain Failure Risk and Emergency Response Protocols
Cold chain failure events (natural disasters: flooding power outages, earthquake damage) may trigger temperature excursion assessments. WHO VVM (Vaccine Vial Monitor) system — photochromic label indicating cumulative heat exposure, gradually deepening in color. 2025 major cold chain event: Severe flooding in South China in June–July 2025 led to ~12–36 hour power outages at county-level CDCs, affecting ~8,000–15,000 HPV doses and ~15,000–20,000 pediatric EPI vaccine doses.
International Trade Risks and Geopolitical Impacts
US BIS entity list, Export Control Reform Act (ECRA) advanced biotechnology export restrictions, and proposed Biosafety Act may limit Chinese companies' access to key mRNA technology-related equipment and raw materials. LNP core patent system (Arbutus Biopharma and Genevant Sciences holding foundational ionizable lipid patents) — domestic mRNA companies entering international markets face potential litigation risk, requiring complete FTO (Freedom to Operate) analysis.
Inventory Buildup and Business Model Vulnerability
Zhifei's 20 billion CNY HPV inventory crisis is China's vaccine industry's deepest risk lesson in 2025. Root causes: highly concentrated single-product agency model + overly optimistic procurement planning based on historical high growth extrapolation + insufficient demand forecasting + inadequate channel inventory transparency. Future vaccine company business models will evolve toward "demand-driven production, dynamic inventory management, multi-product risk diversification."
XI 2026–2030 Market Forecast and Industrial Structure Evolution
Five-Year Market Size Forecast Model
Under the baseline scenario (stable policy, no major safety events), China's vaccine market (excluding COVID-19 specific) will maintain 12–15% CAGR in 2026–2030, potentially breaking 200–250 billion CNY by 2030.
Category-by-category growth attribution:
| Category | 2025 estimate | 2030 forecast | Core driver |
|---|---|---|---|
| HPV vaccines | 10–12 billion | 20–30 billion | EPI volume increase + 9-valent penetration |
| Pneumococcal conjugate | 8–10 billion | 15–20 billion | PCV20/PCV15 + adult expansion |
| Zoster vaccines | 8–12 billion | 30–50 billion | Aging penetration + potential EPI inclusion |
| Influenza vaccines | 4–5 billion | 10–15 billion | Vaccination rate improvement + HD upgrade |
| RSV vaccines | 0 (pre-launch) | 3–8 billion | First domestic/imported launches |
| Rabies vaccines | 2–2.5 billion | 2.5–3.5 billion | Steady growth |
| Others (JE, hepatitis A, EPI) | 15–20 billion | 20–25 billion | Steady EPI procurement growth |
| mRNA non-COVID products | 0 (pre-launch) | 1–3 billion | First flu/RSV mRNA launches |
Optimistic scenario (zoster EPI inclusion, no 9-valent VBP, mRNA influenza succeeds): 2030 market ~250–300 billion CNY. Pessimistic scenario (large-scale VBP, major safety events, economic downturn): ~150–180 billion CNY.
9-Valent HPV Domestic Penetration Forecast
2025: Cecolin 9 in 16 provinces, ~3–5 million doses; Gardasil 9 ~10–15 million doses; combined ~13–20 million. 2026: Cecolin 9 national coverage, ~20–30 million doses; Gardasil 9 ~8–12 million; combined ~30–40 million. 2027–2028: With Watson entry, three brands, combined annual doses potentially 60–80 million; domestic brands combined >70% share. 2030: Domestic 9-valent penetration target 70–80%; Gardasil 9 retaining 20–30%.
China Vaccine Industry International Competitiveness Enhancement Pathway
Five key dimensions: ① WHO PQ certification quantity rapid expansion (from ~10 to 25–30 certified products by 2030); ② LNP/mRNA core patent construction (domestic companies building proprietary LNP IP portfolios); ③ Local manufacturing capability export (Watson-Indonesia Bio Farma PCV13 model replicated across more products and countries); ④ Global clinical research network establishment (GCP-compliant research centers in Africa, Southeast Asia, South Asia); ⑤ International standard alignment (ICH Q5, WHO GMP, ICH Q1A/Q5C, 3Rs principles).
mRNA Vaccine Commercialization Timeline
2026–2027: First domestic mRNA clinical data readouts (influenza mRNA, RSV mRNA), NDA/BLA filings begin; 2027–2028: First domestic mRNA influenza vaccine (optimistic) or first imported mRNA influenza vaccine (e.g., Moderna mRNA-1010 China application) approval; 2028–2030: mRNA RSV vaccine China commercialization; mRNA influenza market begins (10–30 billion CNY scale); Post-2030: mRNA zoster, HPV, and tumor mRNA vaccines entering late clinical or early commercial stages.
Export Scale Forecast
2025 export: ~US$324 million; 2030 target: US$1.5–2 billion (4–6× growth); target market expansion from Pakistan/Brazil/Indonesia to Africa (Kenya, Ethiopia, Nigeria, South Africa), MENA (UAE, Saudi Arabia + GCC), Central Asia (Kazakhstan, Uzbekistan); WHO PQ certified products from ~10 to 25–30 by 2030.
Key Technology Milestone Timeline (2026–2030)
| Year | Expected Technology/Commercial Milestone | Impact Assessment |
|---|---|---|
| 2026 | Cecolin 9 national coverage; PCV20 application progressing | 9-valent HPV competitive landscape essentially set |
| 2026 | Sinovac-Brazil long-term agreement first delivery | China vaccine export amount hits historical high |
| 2027 | Watson 9-valent HPV marketing application (forecast) | Three-brand competition formed |
| 2027 | Beyfortus infant RSV monoclonal China approval | New era of infant RSV prevention begins |
| 2027 | Minhai hexavalent application (forecast) | Historic breakthrough in domestic combination vaccines |
| 2028 | Domestic mRNA influenza Phase I/II data readout | Validates domestic mRNA platform competitiveness |
| 2028 | Adult RSV vaccine (imported) China approval | Zoster/RSV dual-engine driving adult market |
| 2029 | Domestic zoster recombinant vaccine (Shingrix biosimilar) application | Reduced import dependence, further price decline |
| 2030 | First domestic mRNA influenza vaccine approved (optimistic) | mRNA platform commercialization milestone |
| 2030 | WHO PQ certified products reach 25–30 | China vaccine global competitiveness significantly enhanced |
XII Regulatory Pathway, Supply Chain Security, and Industry Investment Analysis
China Vaccine Approval Pathway Full Process Analysis
China's vaccine development to commercial approval requires strictly regulated multi-stage review processes, typically 10–15 years — the highest regulatory threshold among biologics.
Preclinical stage: Vaccine design/candidate screening, process development, animal safety and immunogenicity evaluation, toxicology studies, process scale-up and quality research, GLP compliance requirements. Typically 3–5 years, cost ~50 million to 200 million CNY.
Phase I clinical: 20–100 healthy volunteers, evaluating safety (AE type, frequency, severity) and preliminary immunogenicity. Typically 12–24 months.
Phase II clinical: Hundreds to thousands of volunteers, exploring optimal dose regimen, evaluating different population immune response differences.
Phase III clinical: Thousands to tens of thousands of healthy volunteers in randomized double-blind placebo-controlled trial, validating vaccine efficacy (VE). VE = (1 - attack rate in vaccinated group/attack rate in control group) × 100%, typically targeting VE ≥50% (WHO minimum), most commercial vaccines target 60–90%+. Phase III is the most expensive and longest single stage — a large Phase III typically costs 500 million to 2 billion CNY over 3–6 years.
BLA/NDA and review: Standard review period ~200 working days, priority review ~130 working days. Pre-Approval Inspection (PAI) confirms manufacturing process consistency with application dossier.
Lot release system: Every vaccine batch requires testing certification by NIFDC before market release — typically taking 3–6 months, an incompressible critical path in vaccine production planning.
Post-approval pharmacovigilance: MAH must establish post-market safety monitoring systems per GVP (Good Vigilance Practice) standards, reporting all SUSARs (Suspected Unexpected Serious Adverse Reactions).
International Vaccine Regulatory Comparison: NMPA, FDA, EMA
FDA (CBER): "Risk-benefit comprehensive review" framework; independent advisory committee (VRBPAC) publicly deliberates vaccine data; Rolling Review and Breakthrough Therapy Designation accelerated mechanisms; COVID-19 vaccine BLA review completed in 6 months.
EMA: Multi-Member State collaborative review system; EU official control authority batch release (OCABR). FDA-EMA Confidentiality Arrangement enables non-public information sharing between the two agencies.
NMPA vs. FDA/EMA gaps: Transparency (lower advisory committee meeting public disclosure), review resources, international collaboration (bilateral mutual recognition agreements not yet established), and post-market proactive active surveillance (VSD-level big data monitoring system under construction). NMPA progress: 2015–2018 reforms largely eliminated drug review backlog; MAH system decoupling R&D from manufacturing; accepting overseas clinical data for China applications (ICH E5); rolling review mechanism for COVID-19 vaccines and rare diseases.
Biopharmaceutical GMP Compliance System
Cleanroom classification: A/B grade (ISO 5/7) cleanroom for critical processes (filling), with RABS or isolator. A-grade particle count (≥0.5 μm) ≤3,520/m³; bioburden ≤1 cfu/m³.
Sterilization and sterility assurance: Terminal sterilization or sterile filtration (0.22 μm); Media Fill Test semi-annually, minimum 3,000 units, zero contamination tolerance.
Cold chain full-process control: From cell bank (liquid nitrogen storage) to fermentation (±0.5°C temperature control) to semi-finished storage (2–8°C or lower) to finished product release and transport (specialized refrigerated vehicles).
Environmental monitoring (EM): Suspended particle monitoring, viable microorganism monitoring (RODAC, settle plates, surface sampling, personnel glove/gown sampling) — daily GMP compliance core data.
AEFI System and Vaccine Vigilance Mechanism
AEFI classification: ① Vaccine reactions (directly related to vaccine components); ② program errors (caused by vaccination operation or storage problems); ③ coincidental events (unrelated to vaccine); ④ psychogenic reactions; ⑤ unknown cause events.
Serious AEFI monitoring: Enhanced Safety Surveillance for new vaccines (mRNA, adenovirus vector) in early post-marketing phase, including Sentinel Hospital Surveillance and Vaccine Safety Rapid Response Mechanism. Rare serious AEFIs (e.g., myocarditis/pericarditis after mRNA COVID vaccination, ~1–10/100,000, more common in young males) require detailed recording and regular public reporting.
TXG (Tianxia Gongchang) platform's database of 4.8 million active factories covers pharmaceutical packaging factories, syringe manufacturers, cold chain equipment companies, medical devices manufacturers, and pharmaceutical equipment suppliers — a factory-level data platform for vaccine industry chain companies to conduct supply chain tracing and upstream partner screening, empowering the continuous improvement of China's vaccine manufacturing capabilities.
Vaccine Supply Chain Security and Domestic Substitution Strategy
Enterprise-level supply chain vulnerability assessment (2025):
- Zhifei (300122): High concentration risk from single upstream supplier (Merck); ZF2001 self-developed line dependent on CHO cell culture infrastructure of Zhifei Longma.
- CanSino (688185): Adenovirus vector core biological materials (Ad5 seed stock, HEK293 cell bank) highly autonomous; GMP-grade manufacturing consumables (single-use filter membranes, chromatography resins) partially import-dependent.
- Watson (300142): PCV13 production CRM197 carrier protein self-expressed (partial domestic substitution) in Yunnan Yuxi; main external dependence on chromatography purification consumables (Cytiva, Tosoh brands).
- Hualan Vaccine (301204): Highly dependent on chicken embryo supply; avian influenza outbreaks could directly compress influenza vaccine output — fundamental solution is MDCK cell-based influenza vaccine development.
Key imported raw materials domestication progress:
- Single-use bioreactor bags: Domestic market share ~20–30%, Sartorius/GE (CELL-STK)/Danaher (Pall) still ~70%.
- Ionizable lipids (mRNA LNP): Abogen, Dalian Mozhu, Suzhou Xianto are domestic alternatives but limited commercial scale.
- T7 RNA polymerase: Domestic companies Qingke Bio, Yisheng Bio, Singene making progress; some batches GMP-validated, but large-scale supply quality consistency needs continued validation.
- MPL-type adjuvants: Early research at Xiamen University, Sichuan University West China Hospital; years from large-scale commercial application.
- Chromatography resins: Ion exchange resin domestication making progress (Bogelun Suzhou, Chunyuan Bio Hangzhou); protein A resin domestication rate still low (~10–15%).
Policy support: NDRC and MIIT have listed biopharmaceutical key raw materials domestication in the 14th Five-Year Plan for Bioeconomy Development; NMPA encouraging domestic supplier prioritization.
Vaccine Production Scale Expansion and Strategic Capacity Reserve
Strategic capacity reserve: Post-COVID government emphasizes maintaining "hot standby capacity" (GMP-compliant idle capacity that can quickly switch production during outbreaks). CNBG and Sinovac (SOEs) are included in national biosafety strategic reserve systems.
mRNA capacity construction: Abogen-Watson joint venture's Suzhou base (Aizhong Bio) established the first complete commercial mRNA-LNP GMP production line in China (microfluidic mixing, mRNA IVT system, LNP encapsulation, ultra-low temperature storage facilities).
China Vaccine Industry Investment Analysis and Capital Market Perspective
Listed company capital operations: China's vaccine listed companies in 2025 face dual pressure: fundamental deterioration (HPV price wars, inventory crisis, zoster competition) causing earnings estimate large downward revisions; sector-wide PE multiples from 2021 peak 60–100× to 2025 15–30×.
Market cap as of mid-2025: Zhifei ~10–15 billion CNY (down >90% from 2021 peak of 200+ billion); Wantai ~30–50 billion CNY (9-valent approval short-term catalyst, offset by H1 losses); CanSino ~10–15 billion; Chengda Bio ~5–8 billion; Bavarian Nordic ~3–5 billion; Watson ~15–20 billion.
Valuation logic restructuring: Market transitioning from "agency vaccine revenue linear extrapolation model" to "self-developed innovative pipeline DCF model." Pure agency model companies (Zhifei) severely discounted; self-developed innovative pipeline companies (CanSino, Abogen-expected IPO) getting higher pipeline value premium.
M&A integration trends: As price wars intensify, 2026–2030 M&A acceleration expected: large companies acquiring small/medium companies with specific product approvals or production capacity; traditional vaccine companies (inactivated/recombinant protein) making strategic investments in mRNA, adenovirus vector, VLP new platform companies; overseas asset acquisitions for WHO PQ-certified products in low-income country markets.
XIII Conclusion: Historic Turning Point Where Three Forces Converge
In 2026, China's vaccine industry is at a historic turning point where three forces are deeply converging, and this transformation will reshape the competitive landscape of the entire industry over the next decade.
China's Vaccine Industry Moving from "Quantitative Accumulation" to "Qualitative Leap"
The 2020–2025 vaccine industry development was, in a sense, an accelerated "exam-oriented growth": the COVID-19 pandemic brought unprecedented production pressure and technological demands, and China's vaccine industry completed the world's largest-scale commercialization of COVID-19 inactivated vaccines in an extremely short time, demonstrating the organizational mobilization capability and scale execution capacity of China's biological products manufacturing system. However, structural deficiencies were also exposed: high dependence on single agency models (Zhifei case), insufficient mRNA platform technology accumulation, WHO PQ certification counts far behind India (~10 vs. SII's 30+), and key consumable import dependence not fundamentally resolved.
In 2026–2030, China's vaccine industry will transition from the "quantitative accumulation" phase to the "qualitative leap" phase, with evaluation dimensions shifting from "production volume scale" to "technological autonomy," "innovative pipeline value," "global competitive position," and "supply chain security."
Far-Reaching Impact of HPV Market Structure Evolution
Cecolin 9's 499 CNY/dose launch is not only a market breakthrough for a specific product but also a systematic switching signal of industrial logic: it proves that Chinese vaccine companies have the capability to achieve commercial breakthrough in the globally most difficult 9-valent HPV vaccine category, and proves that VLP technology in Chinese companies has reached globally leading levels (Wantai HPV52/58 antibody GMC data surpassing Gardasil 9 in key indicators).
Merck's response will determine its strategic bottom line in China: maintain high-price, low-volume mode (brand premium preserving some shipment) or price reduction to regain market share (affecting pricing systems in Africa, Southeast Asia). This strategic choice will become clear over the next 2–3 years, directly determining the final market share distribution between Wantai, Watson, and other domestic manufacturers.
mRNA Technology Platform Domestic Competitive Landscape
The domestic mRNA vaccine track competition over the next 5 years will revolve around three axes:
Technology axis: LNP formula patents (proprietary ionizable lipids), mRNA sequence optimization capability (codon optimization algorithms, modified nucleoside chemical synthesis), manufacturing process stability (microfluidic scale-up, TFF buffer exchange, mRNA-LNP consistency control) — these three form mRNA vaccine companies' core technology barriers.
Capital axis: mRNA vaccine clinical research costs (~500 million to 1.5 billion CNY/indication for Phase III) put significant capital pressure on startups. Ability to sustain financing or rely on existing commercial product cash flow is decisive.
Regulatory axis: CDE's maturation of mRNA vaccine review framework (specialized guidelines, reviewer capacity building) will significantly affect candidate product review speed; priority review eligibility forms first-mover advantage.
Systematic Deepening of International Expansion Strategy
China vaccine international expansion 2.0 phase (post-2023) core characteristic is moving from "one-time exports" to "long-term strategic partnerships," from "finished goods trade" to "compound technology + capital + production export." This transition's essence is Chinese vaccine companies leaping from the "low-end manufacturing segment" of the global vaccine value chain to the role of "technology provider and strategic partner."
Force 1: Systematic domestic premium vaccine breakthroughs
Wantai 9-valent HPV vaccine launch at 499 CNY/dose completely shattered Merck's technological and market monopoly in China's 9-valent HPV market — the most important milestone in domestic vaccine self-development since the 2019 domestic bivalent HPV launch. HPV inclusion in EPI provides free protection for eligible girls, marking the HPV prevention policy entering a systematic coverage phase. PCV premium versions imminent (PCV15, PCV20), adult pneumococcal vaccine market about to open, zoster vaccine penetration continuing to rise — these forces combined are driving China's vaccine market from "pediatric-dominated" to a mature "pediatric + adult balanced" structure.
Force 2: Comprehensive technology platform iteration
Post-COVID era, mRNA, adenovirus vector, VLP, AI antigen design, and aerosol inhalation delivery new platforms are rapidly moving toward commercialization, relatively narrowing the technology moat of traditional inactivated and live attenuated vaccines. CanSino's inhaled technology commercialization precedent, Bavarian Nordic's nasal spray continuous iteration, and Abogen's LNP patent breakthroughs all foreshadow China's vaccine industry making steady progress in technological independence. Companies that can systematically master the mRNA + LNP + AI-assisted design combination will occupy decisive first-mover advantage in the next vaccine innovation cycle.
Force 3: Strategic leap in global expansion
Sinovac's 10-year US$700 million+ agreement with Brazil, Watson's PCV13 local production in Indonesia, Wantai's bivalent HPV entering multiple country markets, Chengda Bio's continuous rabies vaccine overseas registration expansion, and CanSino's tuberculosis vaccine Indonesia approval — these developments mark China's vaccine international expansion fully transitioning from "emergency supply" to "long-term strategic positioning." As WHO PQ certification counts gradually catch up with India, Chinese vaccine companies are expected to establish competitive positions comparable to India's Serum Institute of India (SII) in low-and-middle-income country markets by around 2030.
The core competitive proposition of China's vaccine industry for 2026–2030 will fully shift from "speed and scale" to "technological depth and international breadth." Whether Chinese vaccine companies can build proprietary moats in mRNA/LNP patents, shorten capability gaps with global top companies in high-value combination and multivalent products, and achieve systematic breakthroughs in WHO PQ certification and local manufacturing, will ultimately determine whether Chinese vaccine companies can truly join Pfizer, Merck, and GSK in the global vaccine first tier over the next decade.
Data Sources
- Zhifei Biologics (300122) 2025 Semi-annual and Third Quarter Reports, Shenzhen Stock Exchange announcements, 2025
- Watson Bio (Yunnan Watson Biologics, 300142) 2025 Semi-annual Report, cninfo.com.cn, August 2025
- Wantai Bio (Beijing Wantai Bio, 603392) 2025 Semi-annual and Third Quarter Reports, Shanghai Stock Exchange, 2025
- CanSino Biologics (688185) 2025 Semi-annual Report, Shanghai Stock Exchange, 2025
- Changchun Bavarian Nordic (688276) 2025 Third Quarter Report, Shanghai Stock Exchange, 2025
- Chengda Bio (688739) 2025 Semi-annual Report, Shanghai Stock Exchange, 2025
- Pfizer Inc. Form 8-K FY2025 Q1/Q2, SEC EDGAR, 2025
- GSK plc FY2025 Full Year Results Announcement, gsk.com, February 2026
- Moderna Inc. Form 10-Q FY2025 Q1, SEC EDGAR, 2025
- Merck & Co. Form 8-K FY2025, SEC EDGAR; FiercePharma Gardasil coverage, 2025
- NMPA (National Medical Products Administration) Lot Release Data Announcements, nmpa.gov.cn
- National Disease Control and Prevention Administration, "Notice on Work Related to Incorporation of HPV Vaccines into National Immunization Program," ndcpa.gov.cn, November 2025
- Xinhua Net, "Optimizing and Expanding Immunization Strategy, Intelligently Upgrading Vaccination Services — Observations at the 2025 Vaccine and Health Conference," April 2025
- 21st Century Business Herald, "5 Major Vaccine Products Sales Nearing USD 25 billion: MNCs in the Lead, How Can Domestic Pharma Companies Catch Up?" February 2025
- Interface News, "Wantai Bio's First Domestic 9-valent HPV Vaccine Receives Lot Release Approval," June 2025
- QianZhan Economic Analyst, "Contract Value Exceeding USD 700 Million! Sinovac Reaches 10-Year Vaccine Cooperation with Brazil's Ministry of Health," November 2025
- Duke Kunshan University Vaccine Delivery Research and Innovation Lab, "2025 World Immunization Week Media Reference Materials," April 2025
- BioPharma Dive, "GSK delivers strong 2025 performance," 2026
- Tianxia Gongchang (www.tianxiagongchang.com), Active Factory Database, accessed June 2026
- World Health Organization (WHO), Global Vaccine Market Report 2024, Geneva, WHO Press, 2024
- GAVI Alliance, Annual Report 2024: Vaccine Access and Impact Data, gavi.org, 2025
- UNICEF Supply Division, Vaccine Price Data (UNICEF Supply Catalogue), unicef.org/supply, 2025
- National Committee of the Chinese People's Political Consultative Conference Economic Committee, Research Report on High-Quality Development of Biosafety and Vaccine Innovation Industry (Internal Reference Summary), 2025
- Chinese Center for Disease Control and Prevention, 2025 China Influenza Surveillance Annual Report, China CDC Weekly Supplement, 2025
- China CDC National Immunization Program Center, National Immunization Information System Annual Data Summary 2025, China CDC, December 2025
- Frost & Sullivan, China Vaccine Industry Market Research Report 2025, Beijing, 2025
- IQVIA, China Vaccine Market Channel Database 2025 Q2, Beijing, July 2025
- Orient Securities, China Vaccine Industry Deep Report: Landscape Reshaping After the Watershed, September 2025
- Huatai Securities, Vaccine Industry 2026 Annual Strategy: Volume Increase Logic Reshaping, Innovation and International Expansion as Dual Engines, December 2025